MergerLinks Header Logo

Announced

Completed

Viatris completed the acquisition of a 5.1% stake in Syngene from Biocon for $153m.

Synopsis

Viatris, a global pharmaceutical company, completed the acquisition of a 5.1% stake in Syngene, an innovation-led contract research, development and manufacturing organization, from Biocon, an Indian biopharmaceutical company, for $153m.

Principals

SYNGENE

target

SYNGENE

VIATRIS

bidder

VIATRIS

Show Details & Financials

Market Context

Sort

Jonathan Hunt

Jonathan Hunt

ManagerCEO at SYNGENE
Deal Bio
Total Deals
2/
Total Value
£137M
Sibaji Biswas

Sibaji Biswas

ManagerCFO at SYNGENE
Deal Bio
Total Deals
2/
Total Value
£137M
Indranil Sen

Indranil Sen

ManagerCFO at BIOCON BIOLOGICS LTD
Deal Bio
Total Deals
1/
Total Value
£137M
Siddharth Mittal

Siddharth Mittal

ManagerCEO at BIOCON BIOLOGICS LTD
Deal Bio
Total Deals
1/
Total Value
£137M
Chintan Kothari

Chintan Kothari

Financial AdvisorExecutive Director at Avendus
Deal Bio
Total Deals
4/
Total Value
£427M
Gaurav Sood

Gaurav Sood

Financial AdvisorManaging Director & Head, Equity Capital Markets at Avendus
Deal Bio
Total Deals
4/
Total Value
£495M
Sanjeev Narula

Sanjeev Narula

ManagerCFO at VIATRIS
Deal Bio
Total Deals
6/
Total Value
£5,062M
Michael Goettler

Michael Goettler

ManagerCEO at VIATRIS
Deal Bio
Total Deals
3/
Total Value
£18,903M

Search a database of more than 250,000 verified dealmakers

Receive automated updates on global transactions

Follow the activity, relationships and transactions of top dealmakers

No credit card required
Register nowSign up with LinkedIn

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US